WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007022157) APOPTOSIS SENSITIVITY TO AP02L/TRAIL BY TESTING FOR 'GALNAC-T14 EXPRESSION IN CELLS/TISSUES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/022157    International Application No.:    PCT/US2006/031785
Publication Date: 22.02.2007 International Filing Date: 15.08.2006
IPC:
G01N 33/68 (2006.01)
Applicants: GENENTECH, INC. [US/US]; 1 DNA Way, MS 49, South San Francisco, California 94080 (US) (For All Designated States Except US).
WAGNER, Klaus, W. [DE/US]; (US) (For US Only).
ASHKENAZI, Avi, J. [US/US]; (US) (For US Only)
Inventors: WAGNER, Klaus, W.; (US).
ASHKENAZI, Avi, J.; (US)
Agent: MARSCHANG, Diane, L.; c/o GENENTECH, INC., 1 DNA Way, MS 49, South San Francisco, California 94080 (US)
Priority Data:
60/708,677 16.08.2005 US
60/808,076 24.05.2006 US
Title (EN) APOPTOSIS SENSITIVITY TO AP02L/TRAIL BY TESTING FOR 'GALNAC-T14 EXPRESSION IN CELLS/TISSUES
(FR) ANALYSES ET PROCÉDÉS UTILISANT DES BIOMARQUEURS
Abstract: front page image
(EN)Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of GalNac-T related molecules, such as GalNac-T14 or GalNac-T3, is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Kits and articles of manufacture are also provided.
(FR)L'invention concerne des analyses et des procédés qui examinent l'expression d'un ou plusieurs biomarqueurs dans un échantillon de cellule ou de tissu de mammifère. Selon les procédés et les analyses en question, la détection de l'expression de molécules liées à GalNac-T, telles que GalNac-T14 ou GalNac-T3, prédit ou indique que l'échantillon de cellule ou de tissu réagira à des agents inducteurs d'apoptose, notamment les anticorps agonistes Apo2L/TRAIL et anti-DR5. L'invention concerne également des kits et des articles de fabrication.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)